Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

Merck & Co., Inc. MRK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.